Now showing items 197-216 of 838

    • Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis. 

      Morfopoulou, S; Mee, ET; Connaughton, SM; Brown, JR; Gilmour, K; Chong, WKK; Duprex, WP; Ferguson, D; Hubank, M; Hutchinson, C; Kaliakatsos, M; McQuaid, S; Paine, S; Plagnol, V; Ruis, C; Virasami, A; Zhan, H; Jacques, TS; Schepelmann, S; Qasim, W; Breuer, J (2017-01)
      Routine childhood vaccination against measles, mumps and rubella has virtually abolished virus-related morbidity and mortality. Notwithstanding this, we describe here devastating neurological complications associated with ...
    • Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK alpha 2 but not AMPK alpha 1 

      Ashworth, A (2006-05)
      Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK alpha 2 but not AMPK alpha 1 Recent studies indicate that the LKB1 is a key regulator of the AMP-activated protein kinase ( AMPK), which plays a ...
    • Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. 

      Gilbert, DC; Al-Saadi, R; Thway, K; Chandler, I; Berney, D; Gabe, R; Stenning, SP; Sweet, J; Huddart, R; Shipley, JM (2016-03)
      Up to 50% of patients diagnosed with stage I nonseminomatous germ cell tumors (NSGCTs) harbor occult metastases. Patients are managed by surveillance with chemotherapy at relapse or adjuvant treatment up front. Late ...
    • Defining the prognosis of early stage chronic lymphocytic leukaemia patients 

      Hewamana, Saman (2012-02)
      Approximately 70% of chronic lymphocytic leukaemia (CLL) patients present with early stage disease, therefore defining which patients will progress and require treatment is a major clinical challenge. Here, we present the ...
    • Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. 

      Angelis, V; Tippu, Z; Joshi, K; Reis, S; Gronthoud, F; Fribbens, C; Okines, A; Stanway, S; Cottier, E; McGrath, S; Watkins, D; Noble, J; Bhosle, J; Gerlinger, M; Hamid, I; Soliman, H; Nenclares, P; Jones, R; Harrington, K; Gennatas, S (2020-09)
      BACKGROUND:In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their ...
    • Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes 

      Gruszka-Westwood, AM; Hamoudi, R; Osborne, L; Matutes, E; Catovsky, D (WILEY-LISS, 2003-01)
      Splenic lymphoma with villous lymphocytes (SLVL) is a low-grade lymphoproliferative disorder characterized by splenomegaly and circulating villous lymphocytes in the peripheral blood. It is considered to be the leukemic ...
    • Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia 

      Brito-Babapulle, V; Baou, M; Matutes, E; Morilla, R; Atkinson, S; Catovsky, D (BLACKWELL SCIENCE LTD, 2001-08)
      Deletions of 13q14.3 are well known in several malignancies and are thought to be associated with tumour suppressor function. The RB-1 gene is a tumour suppressor gene, but other loci including D13S319 and D13S25 telomeric ...
    • Delineation of the minimal region of loss at 13q14 in multiple myeloma 

      Elnenaei, MO; Hamoudi, RA; Swansbury, J; Gruszka-Westwood, AM; Brito-Babapulle, V; Matutes, E; Catovsky, D (2003-01)
      Previous studies have focused on the incidence and prognostic implications of 13q14 deletions in multiple myeloma (MM), but none has sought to delineate the minimal common deleted region (CDR). In an effort to do so, ...
    • Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. 

      Watts, E; Heidenreich, D; Tucker, E; Raab, M; Strebhardt, K; Chesler, L; Knapp, S; Bellenie, B; Hoelder, S (2019-03)
      Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk ...
    • Designing the future shape of breast cancer diagnosis, prognosis and treatment. 

      Dowsett, M (2004-01)
      Translational research is intended to efficiently and accurately validate the most promising preclinical biomarkers and ensure that their diagnostic or prognostic potential is rapidly adopted in the clinic. Translational ...
    • Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. 

      Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; Griffiths, B; Moorcraft, S-Y; Rana, I; Begum, R; Assiotis, I; Matthews, N; Rao, S; Watkins, D; Chau, I; Cunningham, D; Starling, N; Gerlinger, M (2019-05-27)
      DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ...
    • Detecting repeated cancer evolution in human tumours from multi-region sequencing data 

      Caravagna, G; Giarratano, Y; Ramazzotti, D; Graham, T; Sanguinetti, G; Sottoriva, A (2017-06-27)
      Abstract Carcinogenesis is an evolutionary process driven by the accumulation of genomic aberrations. Recurrent sequences of genomic changes, both between and within patients, reflect repeated evolution that is valuable ...
    • Detecting truly clonal alterations from multi-region profiling of tumours. 

      Werner, B; Traulsen, A; Sottoriva, A; Dingli, D (2017-03-27)
      Modern cancer therapies aim at targeting tumour-specific alterations, such as mutations or neo-antigens, and maximal treatment efficacy requires that targeted alterations are present in all tumour cells. Currently, treatment ...
    • Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. 

      Ahmed, N; Sriskandarajah, P; Burd, C; Riddell, A; Boyd, K; Kaiser, M; Messiou, C (2019-05)
      OBJECTIVE:Current therapies for multiple myeloma, which include corticosteroids, increase risk of avascular necrosis. The aim of this study was to assess incidental detection of femoral head avascular necrosis on routine ...
    • Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry 

      Jain, P; Giustolisi, GM; Atkinson, S; Elnenaei, MO; Morilla, R; Owusu-Ankomah, K; Rafiq-Mohammed, F; Matutes, E; Wotherspoon, A; Catovsky, D (BRITISH MED JOURNAL PUBL GROUP, 2002-12)
      Aims: To describe and revise a flow cytometric assay for evaluating cyclin D1 overexpression in B cell lymphoproliferative disorders (B-LPDs), Methods: Cyclin D1 expression was evaluated in 11 healthy controls and 5 1 ...
    • Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance. 

      Jamin, Y; Eykyn, TR; Poon, E; Springer, CJ; Robinson, SP (2014-04)
      PURPOSE:The purpose of this study is to evaluate if the differential exchange rates with bulk water between amine and amide protons can be exploited using chemical exchange saturation transfer magnetic resonance (CEST-MR) ...
    • Determinants of age at menarche in the United Kingdom: analyses from the Breakthrough Generations Study 

      Ashworth, A; Jones, M; Schoemaker, M; Swerdlow, A (2010)
      Background: Early menarche increases breast cancer risk but, aside from weight, information on its determinants is limited. Methods: Age at menarche data were collected retrospectively by questionnaire from 81 606 women ...
    • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-12)
      The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
    • Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). 

      Talhouk, A; George, J; Wang, C; Budden, T; Tan, TZ; Chiu, DS; Kommoss, S; Leong, HS; Chen, S; Intermaggio, MP; Gilks, B; Nazeran, TM; Volchek, M; Elatre, W; Bentley, RC; Senz, J; Lum, A; Chow, V; Sudderuddin, H; Mackenzie, R; Leong, SCY; Liu, G; Johnson, D; Chen, B; Group, A; Alsop, J; Banerjee, SN; Behrens, S; Bodelon, C; Brand, AH; Brinton, L; Carney, ME; Chiew, Y-E; Cushing-Haugen, KL; Cybulski, C; Ennis, D; Fereday, S; Fortner, RT; García-Donas, J; Gentry-Maharaj, A; Glasspool, R; Goranova, T; Greene, CS; Haluska, P; Harris, HR; Hendley, J; Hernandez, BY; Herpel, E; Jimenez-Linan, M; Karpinskyj, C; Kaufmann, SH; Keeney, GL; Kennedy, CJ; Köbel, M; Koziak, JM; Larson, MC; Lester, J; Lewsley, L-A; Lissowska, J; Lubiński, J; Luk, H; Macintyre, G; Mahner, S; McNeish, IA; Menkiszak, J; Nevins, N; Osorio, A; Oszurek, O; Palacios, J; Hinsley, S; Pearce, CL; Pike, MC; Piskorz, AM; Ray-Coquard, I; Rhenius, V; Rodriguez-Antona, C; Sharma, R; Sherman, ME; De Silva, D; Singh, N; Sinn, P; Slamon, D; Song, H; Steed, H; Stronach, EA; Thompson, PJ; Tołoczko, A; Trabert, B; Traficante, N; Tseng, C-C; Widschwendter, M; Wilkens, LR; Winham, SJ; Winterhoff, B; Beeghly-Fadiel, A; Benitez, J; Berchuck, A; Brenton, JD; Brown, R; Chang-Claude, J; Chenevix-Trench, G; deFazio, A; Fasching, PA; García, MJ; Gayther, SA; Goodman, MT; Gronwald, J; Henderson, MJ; Karlan, BY; Kelemen, LE; Menon, U; Orsulic, S; Pharoah, PDP; Wentzensen, N; Wu, AH; Schildkraut, JM; Rossing, MA; Konecny, GE; Huntsman, DG; Huang, RY-J; Goode, EL; Ramus, SJ; Doherty, JA; Bowtell, DD; Anglesio, MS (2020-06-17)
      PURPOSE:Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation ...